Progress toward an integrated understanding of Parkinson's disease
- PMID: 28751973
- PMCID: PMC5510019
- DOI: 10.12688/f1000research.11820.1
Progress toward an integrated understanding of Parkinson's disease
Abstract
Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease, affecting over 10 million individuals worldwide. While numerous effective symptomatic treatments are currently available, no curative or disease-modifying therapies exist. An integrated, comprehensive understanding of PD pathogenic mechanisms will likely address this unmet clinical need. Here, we highlight recent progress in PD research with an emphasis on promising translational findings, including (i) advances in our understanding of disease susceptibility, (ii) improved knowledge of cellular dysfunction, and (iii) insights into mechanisms of spread and propagation of PD pathology. We emphasize connections between these previously disparate strands of PD research and the development of an emerging systems-level understanding that will enable the next generation of PD therapeutics.
Keywords: PD; Parkinson's disease; Parkinson's disease genetics; neurodegenerative disorders; α-Synuclein.
Conflict of interest statement
Competing interests: Maxime W.C. Rousseaux and Joshua M. Shulman declare that they have no disclosures. Joseph Jankovic has received research or training grants and/or has served as a consultant for the Michael J. Fox Foundation for Parkinson’s Research, Prothena Biosciences Inc, and Teva Pharmaceutical Industries Ltd.No competing interests were disclosed.No competing interests were disclosed.
Figures
References
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
